Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Background Preclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET
TKIs are a possible treatment for EGFR mutation-positive lung cancers with MET-driven …

Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …